Abstract
The 3p21.3 tumour suppressor gene (TSG) RASSF1A is inactivated predominantly by promoter methylation and rarely by somatic mutations. Recently we demonstrated that epigenetic inactivation of RASSF1A is frequent in both clear cell and papillary adult renal cell carcinomas (even though 3p21.3 allele loss is rare in papillary tumours). Wilms' tumour is the most common childhood kidney tumour, but relatively little is known about its molecular pathogenesis. Thus TSGs such as WT1, p16(CDKN2a) and p53 are inactivated in only a minority of cases. In view of the involvement of RASSF1A in adult renal cancers we investigated RASSF1A as a candidate Wilms' TSG. We detected RASSF1A hypermethylation in 21 of 39 (54%) primary Wilms' tumours. 3p21.3 allele loss was not detected in nine informative Wilms' tumours (five with RASSF1A methylation). In contrast to RASSF1A, only a minority (10.3%) of Wilms' tumours demonstrated p16 promoter methylation. As chromosome 3p allele loss is frequent in colorectal cancer, we proceeded to investigate RASSF1A promoter methylation in colorectal cancer and detected RASSF1A methylation in 80% (4/5) colorectal cancer cell lines and 45% (13/29) primary colorectal cancers. There was no correlation between RASSF1A and p16 methylation in colorectal cancer. We have demonstrated that RASSF1A inactivation is the most frequent genetic or epigenetic event yet reported in Wilms' tumourigenesis and that allelotyping studies may fail to identify regions containing important TSGs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD, Maher ER, Latif F . 2001 Oncogene 20: 1509–1518
Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP . 1998 Cancer Res. 58: 5489–5494
Arcellana-Panlilio MY, Egeler RM, Ujack E, Pinto A, Demetrick DJ, Robbins SM, Coppes MJ . 2000 Gene Chromosome Cancer 29: 63–69
Astuti D, Agathanggelou A, Honorio S, Dallol A, Martinsson T, Kogner P, Cummins C, Neumann HP, Voutilainen R, Dahia P, Eng C, Maher ER, Latif F . 2001 Oncogene 20: 7573–7577
Bardeesy N, Falkoff D, Petruzzi MJ, Nowak N, Zabel B, Adam M, Aguiar MC, Grundy P, Shows T, Pelletier J . 1994 Nat. Genet. 7: 91–97
Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP . 1998 Adv. Cancer Res. 72: 141–196
Burbee DG, Forgacs E, Zöchbauer-Müller S, Shivakumar L, Gao B, Randle D, Virmani A, Bader S, Sekido Y, Latif F, Fong K, Gazdar AF, Lerman MI, White M, Minna JD . 2001 J. Natl. Cancer Inst. 93: 691–699
Costello JF, Plass C . 2001 J. Med. Genet. 38: 285–303
Cui H, Horon IL, Ohlsson R, Hamilton SR, Feinberg AP . 1998 Nat. Med. 4: 1276–1280
Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP . 2000 Nat. Genet. 25: 315–319
Davies R, Moore A, Schedl A, Bratt E, Miyahawa K, Ladomery M, Miles C, Menke A, van Heyningen V, Hastie N . 1999 Cancer Res. 59: Suppl S1747–S1750 discussion S1751
Hao X, Willis IE, Pretlow TG, Rao JS, MacLennan GT, Talbot IC, Pretlow TR . 2000 Cancer Res. 60: 18–21
Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB . 1996 Proc. Natl. Acad. Sci. USA 93: 9821–9826
Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM . 1994 Proc. Natl. Acad. Sci. USA 91: 9700–9704
Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB . 1998 Proc. Natl. Acad. Sci. USA 95: 6870–6875
Issa JP, Vertino PM, Boehm CD, Newsham IF, Baylin SB . 1996 Proc. Natl. Acad. Sci. USA 93: 11757–11762
Jones PA . 1999 Trends Genet. 15: 34–37
Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM, Kolodner R . 1997 Cancer Res. 57: 808–811
Lee SB, Haber DA . 2001 Exp. Cell Res. 264: 74–99
Lerman MI, Minna JD . 2000 Cancer Res. 60: 6116–6133
Luo XN, Reddy JC, Yeyati PL, Idris AH, Hosono S, Haber DA, Licht JD, Atweh GF . 1995 Oncogene 11: 743–750
Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D, Morgan NV, Moch H, Richards FM, Kishida T, Yao M, Schraml P, Latif F, Maher ER . 2001 Cancer Res. 61: 7277–7281
Moulton T, Crenshaw T, Hao Y, Moosikasuwan J, Lin N, Dembitzer F, Hensle T, Weiss L, McMorrow L, Loew T, Kraus W, Gerald W, Tycko B . 1994 Nat. Genet. 7: 440–447
Okamoto K, Morison IM, Taniguchi T, Reeve AE . 1997 Proc. Natl. Acad. Sci. USA 94: 5367–5371
Pao MM, Tsutsumi M, Liang G, Uzvolgyi E, Gonzales FA, Jones PA . 2001 Hum. Mol. Genet. 10: 903–910
Richards FM, Schofield PN, Fleming S, Maher ER . 1996 Hum. Mol. Genet. 5: 639–644
Steenman MJ, Rainier S, Dobry CJ, Grundy P, Horon IL, Feinberg AP . 1994 Nat. Genet. 7: 433–439
Stirzaker C, Millar DS, Paul CL, Warnecke PM, Harrison J, Vincent PC, Frommer M, Clark SJ . 1997 Cancer Res. 57: 2229–2237
Thiagalingam S, Lisitsyn NA, Hamaguchi M, Wigler MH, Willson JK, Markowitz SD, Leach FS, Kinzler KW, Vogelstein B . 1996 Cancer Res. 56: 2936–2939
Toyota M, Ohe-Toyota M, Ahuja N, Issa JPJ . 2000 Proc. Natl. Acad. Sci. USA 97: 710–715
Tycko B . 2000 J. Clin. Invest. 105: 401–407
van Engeland M, Roemen GM, Brink M, Pachen MM, Weijenberg MP, de Bruine AP, Arends JW, van den Brandt PA, de Goeij AF, Herman JG . 2002 Oncogene 21: 3792–3795
Vos MD, Ellis CA, Bell A, Birrer MJ, Clark GJ . 2000 J. Biol. Chem. 275: 35669–35672
Waber PG, Chen J, Nisen PD . 1993 Cancer 72: 3732–3738
Acknowledgements
We thank Carol Hardy for 11p LOH analysis and Dr FM Richards, Dr J Kingdom and Dr L Wong for human foetal RNA. We also thank the Association for International Cancer Research, Cancer Research Campaign and SPARKS for financial support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wagner, K., Cooper, W., Grundy, R. et al. Frequent RASSF1A tumour suppressor gene promoter methylation in Wilms' tumour and colorectal cancer. Oncogene 21, 7277–7282 (2002). https://doi.org/10.1038/sj.onc.1205922
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205922
Keywords
This article is cited by
-
Immunohistochemical Profile of Tumor Suppressor Proteins RASSF1A and LATS1/2 in Relation to p73 and YAP Expression, of Human Inflammatory Bowel Disease and Normal Intestine
Pathology & Oncology Research (2020)
-
Interrelations of Apoptotic and Cellular Senescence Genes Methylation in Inflammatory Bowel Disease Subtypes and Colorectal Carcinoma in Egyptians Patients
Applied Biochemistry and Biotechnology (2019)
-
LncRNAs with miRNAs in regulation of gastric, liver, and colorectal cancers: updates in recent years
Applied Microbiology and Biotechnology (2019)
-
Comparative methylome analysis identifies new tumour subtypes and biomarkers for transformation of nephrogenic rests into Wilms tumour
Genome Medicine (2015)
-
Methylome analysis identifies a Wilms tumor epigenetic biomarker detectable in blood
Genome Biology (2014)